小分子抗病毒药物开发的新视角用于RNA病毒
Shasha Li1, Huixia Li2, Ruiya Lian1
1College of Life Science and Engineering, Northwest Minzu University, Lanzhou, 730030, China; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China.
Virology
|March 16, 2024
概括
像导致COVID-19病毒这样的RNA病毒是一个主要威胁. 使用人工智能和其他技术的新抗病毒药物策略正在出现,以对抗这些传染病.
科学领域:
- 病毒学 病毒学
- 传染性疾病 传染性疾病
- 药物发现 药物发现 药物发现
背景情况:
- RNA病毒具有很高的变异性,促进动物传播,并导致全球健康面临重大挑战,包括艾滋病,肝炎,埃博拉病毒,寨卡病毒,登革热和COVID-19.
- 现有的病毒性疾病仍然普遍存在,新出现的传染病对全球公共卫生系统构成持续威胁.
研究的目的:
- 审查当前的策略和开发小分子抗病毒药物的新目标,以对抗RNA病毒.
- 通过分析对高度致病性RNA病毒的进展,为未来的抗病毒药物开发提供见解.
主要方法:
- 分析针对高度致病性RNA病毒的抗病毒药物开发的最新进展.
- 整合来自人工智能,生物信息学,分子生物学和结构生物学的见解.
主要成果:
- 针对抗病毒开发的新策略和药物标的出现.
- 确定推动小分子抗病毒疗法对抗RNA病毒的关键领域.
结论:
- 开发有效的,广泛的抗病毒药物对于应对当前和未来的RNA病毒威胁至关重要.
- 结合现代技术的跨学科方法对于发现新型抗病毒剂至关重要.
相关概念视频
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Retrovirus Life Cycles
45.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.9K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
Small interfering RNAs (siRNA)
3.5K
3.5K
Ribozymes
12.3K
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can...
Ribozymes can...
12.3K


